In most of the studies including DAPA-HF (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure), EMPEROR-Preserved (Empagliflozin outcome trial in patients with chronic HF with Preserved Ejection Fraction) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure), SGLT-2 use was not associated with decreased AF incidence [6, 37, 38]. The gene discussed is SLC5A2; the disease is heart failure.